Abd El-Fattah Ragab, FatmaMahmoud Eid, NahedSayed Hassan, GhaneyaMohammed Nissan, Yassin2019-10-212019-10-2120111) Mosely M. J., J. Natl. Med. Assoc., 45, 192—195 (1953). 2) Ahmad S., Bhanji A., Pal S., Karim M., Int. J. Clin. Pharmacol. Ther., 48, 514—516 (2010). 3) Ray W. A., Varas-Lorenzo C., Chung C. P., Castellsaque J., Murray K. T., Stein C. M., Daugherty J. R., Arbogast P. G., García- Rodríguez L. A., Circ. Cardiovasc. Qual. Outcomes, 2, 155—163 (2009). 4) Marret E., Kurdi O., Zufferey P., Bonnet F., “Database of Abstracts of Reviews of Effects (DARE),” Copyright © 2008, University of York, U.K. 5) Bjarnason I., Hayllar J., MacPherson A. J., Russell A. S., Gastroenterology, 104, 1832—1847 (1993). 6) Lim Y. J., Lee J. S., Ku Y. S., Hahm K. B., J. Gastroenterol. Hepatol., 24, 1169—1178 (2009). 7) Yamamoto Y., Toyohara J., Ishiwata K., Sano K., Yamamoto F., Mukai T., Maeda M., Chem. Pharm. Bull., 59, 938—946 (2011). 8) Eren G., Unlü S., Nuñez M. T., Labeaga L., Ledo F., Entrena A., Banoğlu E., Costantino G., Sahin M. F., Bioorg. Med. Chem., 18, 6367—6376 (2010). 9) Ghate M., Kusanur R. A., Kulkarni M. V., Eur. J. Med. Chem., 40, 882—887 (2005). 10) Jadhav V. B., Kulkarni M. V., Rasal V. P., Biradar S. S., Vinay M. D., Eur. J. Med. Chem., 43, 1721—1729 (2008). 11) Heidari M. R., Foroumadi A., Noroozi H., Samzadeh-Kermani A., Azimzadeh B. S., Pak. J. Pharm. Sci., 22, 395—401 (2009). 12) Tan Y. X., Gong T., Liu C., Chen R. Y., Yu D. Q., Chem. Pharm. Bull., 58, 579—581 (2010). 13) Brown M. E., Fitzner J. N., Stevens T., Chin W., Wright C. D., Boyce J. P., Bioorg. Med. Chem., 16, 8760—8764 (2008). 14) Giitschow M., Neumann U., Bioorg. Med. Chem., 5, 1935—1942 (1997). 15) Maguire A. R., Plunkett S. J., Papot S., Clynes M., O’Connor R., Touhey S., Bioorg. Med. Chem., 9, 745—762 (2001). 16) Tran T. D., Park H., Kim H. P., Ecker G. F., Thai K. M., Bioorg. Med. Chem. Lett., 19, 1650—1653 (2009). 17) Kumar S., Singh B. K., Pandey A. K., Kumar A., Sharma S. K., Raj H. G., Prasad A. K., Van der Eycken E., Parmar V. S., Ghosh B., Bioorg. Med. Chem., 15, 2952—2962 (2007). 18) Schonberg A., Badran N., Starkovsky A. N., J. Am. Chem. Soc., 75, 4992—4995 (1953). 19) Baciocchi E., Clementi S., Sebastiani G., J. Chem. Soc., Perkin Trans. II, 1976, 266—271 (1976). 20) Hassan G. S., Hegazy G. H., Safwat H. M., Arch. Pharm. Chem. Life Sci., 339, 448—455 (2007). 21) Waisser K., Hladuvková J., Gregor J., Rada T., Kubicová L., Klimesová V., Kaustová J., Arch. Pharm. (Weinheim), 331, 3—6 (1998). 22) Waisser K., Gregor J., Kubicová L., Klimesová V., Kunes J., Machácek M., Kaustová J., Eur. J. Med. Chem., 35, 733—741 (2000). 23) Schonberg A., Sina A., J. Am. Chem. Soc., 72, 1611—1616 (1950). 24) Winter C. A., Risley E. A., Nuss G. W., Proc. Soc. Exp. Biol. Med., 111, 544—547 (1962). 25) Di Rosa M., Willoughby D. A., J. Pharm. Pharmacol., 23, 297—298 (1971). 26) Farman N., Pradelles P., Bonvalet J. P., Am. J. Physiol., 251, 238— 244 (1986). 27) Rainsford K. D., Agents Actions, 7, 573—577 (1977). 28) Rowlinson S. W., Kiefer J. R., Prusakiewicz J. J., Pawlitz J. L., Kozak K. R., Kalgutkar A. S., Stallings W. C., Kurumbail R. G., Marnett L. J., J. Biol. Chem., 278, 45763—45769 (2003). 29) Tewari A. K., Srivastava P., Singh V. P., Singh A., Goel R. K., Mohan C. G., Chem. Pharm. Bull., 58, 634—638 (2010). 30) Rieke C. J., Mulichak A. M., Garavito R. M., Smith W. L., J. Biol. Chem., 274, 17109—17114 (1999). 31) Harrak Y., Casula G., Basset J., Rosell G., Plescia S., Raffa D., Cusimano M. G., Pouplana R., Pujol M. D., J. Med. Chem., 53, 6560—6571 (2010).https://doi.org/https://cutt.ly/prX7krrMSA Google ScholarNew series of furosalicylic acids 3a—c, furosalicylanilides 6a—n, furobenzoxazines 8a—f, 1-benzofuran- 3-arylprop-2-en-1-ones 12a,b, 6-(aryl-3-oxoprop-1-enyl)-4H-chromen-4-ones 16a—c and 6-[6-aryl-2-thioxo- 2,5-dihydropyrimidin-4-yl]-4H-chromen-4-ones 17a—c were synthesized. Anti-inflammatory activity evaluation was performed using carrageenan-induced paw edema model in rats and prostaglandin E2 (PGE2) synthesis inhibition activity. Some of the tested compounds revealed comparable activity with less ulcerogenic effect than Diclofenac at a dose 100 mg/kg. All the synthesized compounds were docked on the active site of cyclooxygenase-2 (COX-2) enzyme and most of them showed good interactions with the amino acids of the active site comparable to the interactions exhibited by Diclofenac.enanti-inflammatory activityprostaglandin E2benzofuranenzopyran-4-oneArticlehttps://doi.org/